Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Aprea Therapeutics ( (APRE) ).
Aprea Therapeutics, Inc., a clinical-stage precision oncology company developing targeted therapies for biomarker-defined cancers, has advanced a pipeline led by APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, for solid tumor indications. Its mutation-focused approach seeks to selectively kill tumor cells while sparing normal tissue, addressing a broad set of cancers including ovarian, endometrial, colorectal, and head and neck tumors.
On March 31, 2026, Aprea closed an oversubscribed private placement, raising approximately $30 million in gross proceeds to fund general corporate purposes and R&D, notably the ongoing ACESOT-1051 study of APR-1051. The financing, led by Soleus Capital with participation from new and existing investors, underscores investor confidence in Aprea’s WEE1 inhibitor strategy and will support expansion into selected patient populations, including uterine serous carcinoma and cyclin E-overexpressing, platinum-resistant ovarian cancer.
The most recent analyst rating on (APRE) stock is a Buy with a $1.20 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, zero 2025 revenue, and continued cash burn) and poor technicals (price below key moving averages with negative MACD). Offsetting these, corporate events are a notable positive due to the $30M financing extending runway and early clinical response signals, but valuation remains constrained by a negative P/E.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted therapies for patients with biomarker-defined cancers. Its lead programs include APR-1051, an oral small-molecule WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications across multiple cancer types, including ovarian and endometrial cancers.
The company’s approach aims to exploit vulnerabilities associated with cancer cell mutations to kill tumors while minimizing effects on healthy cells. This strategy is designed to be applicable across a range of tumors, such as colorectal and head and neck squamous cell carcinoma, positioning Aprea in the competitive field of next-generation, mutation-driven oncology treatments.
Average Trading Volume: 2,308,578
Technical Sentiment Signal: Sell
Current Market Cap: $8.74M
See more data about APRE stock on TipRanks’ Stock Analysis page.